Sanofi offers refunds for Cablivi in novel model for rebates
As risk sharing agreements slowly make their mark, Sanofi’s new Cablivi warranty program presents a newer take on existing methods.

As risk sharing agreements slowly make their mark, Sanofi’s new Cablivi warranty program presents a newer take on existing methods.
The Xiannuoxin and VV116 oral small-molecule drugs are developed to treat mild to moderate Covid-19 adult patients.
The global pharmaceutical industry experienced an 11% rise in new job postings related to robotics in Q3 2022 compared with…
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Health Canada accepts Veru’s Covid-19 therapy NDS-CV for review
South Korea authorises Novavax Covid-19 vaccine as booster dose
BioNTech to buy UK-based AI company InstaDeep
India’s Hetero receives WHO approval for Nirmacom to treat Covid-19